Developer docs
API playgroundTry for free, no card

Search company profiles

HyperMed Imaging, Inc.

Full company profile

uuid0003kwb

Namestring
HyperMed Imaging, Inc.
Legal namestring
HyperMed Imaging, Inc.
Websiteurl
hypermed.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

HyperMed Imaging, Inc. is a privately held medical device company and the self-described established leader in hyperspectral medical imaging for superficial tissue oximetry. The company has operated in this space since its first-generation OxyVu-1 system received FDA clearance in 2006, and is a wholly controlled subsidiary (by trademark) of SafetySpect, Inc. Its core technology is a proprietary form of hyperspectral imaging that uses visible light directed at the skin surface and a spectrometer to measure light absorption in hemoglobin molecules, differentiating oxygenated from deoxygenated hemoglobin without patient contact and without injectable contrast agents. The product outputs two-dimensional, color-coded maps showing oxyhemoglobin, deoxyhemoglobin and oxygen saturation values, enabling clinicians to assess superficial tissue perfusion adequacy.

The company's commercial product is HyperView, a handheld, battery-operated portable successor to the legacy cart-based OxyVu-1. HyperView received FDA 510(k) clearance in January 2017 and CE Mark approval in April 2018, enabling distribution in the United States and Europe. The device targets wound care specialists, vascular surgeons and reconstructive surgeons who use superficial tissue oxygenation data to inform limb preservation and limb salvage decisions, particularly for patients with diabetes, peripheral vascular disease, and chronic non-healing wounds. The company holds over 60 issued patents and 40+ pending applications worldwide on its hyperspectral medical imaging technology.

HyperMed's business model is hardware sales of the HyperView device through direct enterprise field sales to physicians and healthcare institutions, with marketing presence at vascular, wound care and reconstructive surgery conferences in the US and Europe. Pricing is not publicly disclosed, and the most recent firmographic data indicates the company is not currently offering any medical device for sale. The company is small (1-10 employees), relocated its headquarters from Greenwich, CT to Memphis, TN in February 2015, and has raised approximately $10M in disclosed funding across a 2007 Greenwich Venture Capital Advisors round, a 2014 Series B, and a 2018 round. CEO Mark Darty has led the company since January 2012.

Short descriptiontext

HyperMed Imaging, Inc. is a privately held medical device company that develops and commercializes the HyperView hyperspectral imaging system for non-contact assessment of superficial tissue oxygenation, serving wound care, vascular and reconstructive surgery specialists evaluating perfusion in patients with circulatory compromise.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMemphis, United States
HQ citystring
Memphis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hyperspectral medical imaging, tissue oximetry devices, medical diagnostic imaging, wound care imaging, vascular assessment devices
Industry1 code
PRIMARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
  • Optical Instruments & Lenses3827
Product category
Medical Imaging Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

HyperMed generates revenue through the sale of its HyperView hyperspectral imaging medical device. The company commercialized the first generation OxyVu-1 hyperspectral imaging device and has developed a smaller, more portable product (HyperView) which is FDA 510(k) cleared and CE marked for distribution in the US and Europe.

hypermed.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1OxyVu-1
Description

First generation hyperspectral imaging device, FDA cleared in 2006, cart-based mobile imaging system no longer being produced or sold.

hypermed.com
+1 more record
Core offering1 text field

HyperMed Imaging, Inc. develops and commercializes proprietary hyperspectral medical imaging devices for non-invasive assessment of superficial tissue oxygenation. Its flagship HyperView device is a handheld, battery-operated, portable diagnostic imaging system that uses visible light and a spectrometer to measure light absorption in hemoglobin molecules, producing color-coded maps of oxyhemoglobin, deoxyhemoglobin, and oxygen saturation in superficial tissue without patient contact or injectable contrast.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

HyperMed Imaging, Inc. is the established leader in medical hyperspectral imaging for superficial tissue oximetry. The company offers two products: the legacy OxyVu-1 (FDA cleared in 2006, cart-based mobile imaging system) and its successor HyperView (FDA 510(k) cleared and CE Mark approved handheld, battery-operated portable device). Both products utilize proprietary hyperspectral imaging technology to assess tissue oxygenation by measuring light absorption in hemoglobin molecules, displaying color-coded maps of oxyhemoglobin, deoxyhemoglobin, and oxygen saturation. The HyperView represents the current commercial focus, being smaller, faster, and more portable than its predecessor.

Product and service2 records
1HyperView
CategoryMedical Imaging Device
Description

A handheld, battery-operated, portable diagnostic imaging device for assessing tissue oxygenation non-invasively without patient contact. Reports oxygen saturation (O2Sat), oxyhemoglobin level (Oxy), and deoxyhemoglobin level (Deoxy) in superficial tissue through proprietary hyperspectral imaging. FDA 510(k) cleared and CE Mark approved for distribution in the US and Europe.

2OxyVu-1
CategoryMedical Imaging Device (Legacy)
Description

First-generation cart-based hyperspectral imaging system FDA cleared in 2006 for assessing oxyhemoglobin, deoxyhemoglobin, and oxygen saturation in superficial tissue. Legacy product no longer being produced or sold; replaced by the handheld HyperView device.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HyperMed Imaging, Inc.

Medical Imaging Deviceshypermed.com

HyperMed Imaging, Inc. is a privately held medical device company that develops and commercializes the HyperView hyperspectral imaging system for non-contact assessment of superficial tissue oxygenation, serving wound care, vascular and reconstructive surgery specialists evaluating perfusion in patients with circulatory compromise.

What HyperMed Imaging, Inc. does

HyperMed Imaging, Inc. is a privately held medical device company and the self-described established leader in hyperspectral medical imaging for superficial tissue oximetry. The company has operated in this space since its first-generation OxyVu-1 system received FDA clearance in 2006, and is a wholly controlled subsidiary (by trademark) of SafetySpect, Inc. Its core technology is a proprietary form of hyperspectral imaging that uses visible light directed at the skin surface and a spectrometer to measure light absorption in hemoglobin molecules, differentiating oxygenated from deoxygenated hemoglobin without patient contact and without injectable contrast agents. The product outputs two-dimensional, color-coded maps showing oxyhemoglobin, deoxyhemoglobin and oxygen saturation values, enabling clinicians to assess superficial tissue perfusion adequacy.

The company's commercial product is HyperView, a handheld, battery-operated portable successor to the legacy cart-based OxyVu-1. HyperView received FDA 510(k) clearance in January 2017 and CE Mark approval in April 2018, enabling distribution in the United States and Europe. The device targets wound care specialists, vascular surgeons and reconstructive surgeons who use superficial tissue oxygenation data to inform limb preservation and limb salvage decisions, particularly for patients with diabetes, peripheral vascular disease, and chronic non-healing wounds. The company holds over 60 issued patents and 40+ pending applications worldwide on its hyperspectral medical imaging technology.

HyperMed's business model is hardware sales of the HyperView device through direct enterprise field sales to physicians and healthcare institutions, with marketing presence at vascular, wound care and reconstructive surgery conferences in the US and Europe. Pricing is not publicly disclosed, and the most recent firmographic data indicates the company is not currently offering any medical device for sale. The company is small (1-10 employees), relocated its headquarters from Greenwich, CT to Memphis, TN in February 2015, and has raised approximately $10M in disclosed funding across a 2007 Greenwich Venture Capital Advisors round, a 2014 Series B, and a 2018 round. CEO Mark Darty has led the company since January 2012.

HyperMed Imaging, Inc. firmographics

Firmographics
Name
HyperMed Imaging, Inc.
Legal name
HyperMed Imaging, Inc.
Website
https://hypermed.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
HyperMed Imaging, Inc. is a privately held medical device company that develops and commercializes the HyperView hyperspectral imaging system for non-contact assessment of superficial tissue oxygenation, serving wound care, vascular and reconstructive surgery specialists evaluating perfusion in patients with circulatory compromise.
Ownership category
akta.pro rank

HyperMed Imaging, Inc. industry classification

Industry
Product category
Medical Imaging Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Hyperspectral medical imaging
  • Tissue oximetry devices
  • Medical diagnostic imaging
  • Wound care imaging
  • Vascular assessment devices

Where HyperMed Imaging, Inc. is headquartered

Location

Headquarters

HQ city
Memphis
HQ country
United States
HQ region
North America

Offices2 records

Markets served

HyperMed Imaging, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Others

Revenue model

  1. Medical Device Sales: HyperMed generates revenue through the sale of its HyperView hyperspectral imaging medical device. The company commercialized the first generation OxyVu-1 hyperspectral imaging device and has developed a smaller, more portable product (HyperView) which is FDA 510(k) cleared and CE marked for distribution in the US and Europe.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

HyperMed Imaging, Inc. product offering

Product offering

Core offering

HyperMed Imaging, Inc. develops and commercializes proprietary hyperspectral medical imaging devices for non-invasive assessment of superficial tissue oxygenation. Its flagship HyperView device is a handheld, battery-operated, portable diagnostic imaging system that uses visible light and a spectrometer to measure light absorption in hemoglobin molecules, producing color-coded maps of oxyhemoglobin, deoxyhemoglobin, and oxygen saturation in superficial tissue without patient contact or injectable contrast.

Product overview

HyperMed Imaging, Inc. is the established leader in medical hyperspectral imaging for superficial tissue oximetry. The company offers two products: the legacy OxyVu-1 (FDA cleared in 2006, cart-based mobile imaging system) and its successor HyperView (FDA 510(k) cleared and CE Mark approved handheld, battery-operated portable device). Both products utilize proprietary hyperspectral imaging technology to assess tissue oxygenation by measuring light absorption in hemoglobin molecules, displaying color-coded maps of oxyhemoglobin, deoxyhemoglobin, and oxygen saturation. The HyperView represents the current commercial focus, being smaller, faster, and more portable than its predecessor.

Differentiator

Problem solved

Functional benefit

Brands

  • OxyVu-1: First generation hyperspectral imaging device, FDA cleared in 2006, cart-based mobile imaging system no longer being produced or sold.
  • HyperView

Products and services

  • HyperView A handheld, battery-operated, portable diagnostic imaging device for assessing tissue oxygenation non-invasively without patient contact. Reports oxygen saturation (O2Sat), oxyhemoglobin level (Oxy), and deoxyhemoglobin level (Deoxy) in superficial tissue through proprietary hyperspectral imaging. FDA 510(k) cleared and CE Mark approved for distribution in the US and Europe.
  • OxyVu-1 First-generation cart-based hyperspectral imaging system FDA cleared in 2006 for assessing oxyhemoglobin, deoxyhemoglobin, and oxygen saturation in superficial tissue. Legacy product no longer being produced or sold; replaced by the handheld HyperView device.

Companies that use HyperMed Imaging, Inc.

Customer profile

Segments2 records

Ideal customer profiles1 record

HyperMed Imaging, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

HyperMed Imaging, Inc. partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

HyperMed Imaging, Inc. competitors and assessment

Company assessment

Market position

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

HyperMed Imaging, Inc. social profiles

Digital presence

HyperMed Imaging, Inc. compliance and trust

Trust signal

Compliance3 records

HyperMed Imaging, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HyperMed Imaging, Inc. leadership team

Management profile

Number of profiles

Profiles3 records

HyperMed Imaging, Inc. funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HyperMed Imaging, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HyperMed Imaging, Inc.

What does HyperMed Imaging, Inc. do?

HyperMed Imaging, Inc. develops and commercializes proprietary hyperspectral medical imaging devices for non-invasive assessment of superficial tissue oxygenation. Its flagship HyperView device is a handheld, battery-operated, portable diagnostic imaging system that uses visible light and a spectrometer to measure light absorption in hemoglobin molecules, producing color-coded maps of oxyhemoglobin, deoxyhemoglobin, and oxygen saturation in superficial tissue without patient contact or injectable contrast.

Is HyperMed Imaging, Inc. a public or private company?

HyperMed Imaging, Inc. is a private company. It is classified as corporate owned and is currently operating.

When was HyperMed Imaging, Inc. founded?

HyperMed Imaging, Inc. was founded in 2006. It employs 1 to 10 people.

Where is HyperMed Imaging, Inc. based?

HyperMed Imaging, Inc. is headquartered in Memphis, United States, in the North America region.

How does HyperMed Imaging, Inc. make money?

One revenue line is on record: medical Device Sales.

Does HyperMed Imaging, Inc. have an API?

No public API is recorded for HyperMed Imaging, Inc..

What industry is HyperMed Imaging, Inc. in?

HyperMed Imaging, Inc.'s product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireSafetySpect Acquires FDA-Cleared HyperMed Imaging Technology; Biomark Capital Acquires Ownership Interest in SafetySpectSafetySpect Inc. has acquired key assets, including the FDA-cleared HyperView™ technology and intellectual property portfolio, from HyperMed Imaging Inc. Concurrently, Biomark Capital acquired an ownership interest in SafetySpect to support its expansion into next-generation medical platforms. The company plans to enhance these capabilities using AI and edge-computing architectures while expanding manufacturing through partner ComDel Innovation.openPR.comGlobal Blood Perfusion Imaging Device Market Size & Share Analysis - By Product Type, By Application, By Region - Forecasts (2024 - 2031)The global blood perfusion imaging device market is projected to grow at a CAGR of 10.20% from 2024 to 2031, driven by chronic disease prevalence and technological advances. The market is segmented by product type (portable, desktop) and application (hospital, clinic, surgery center), with key players including RFPi, Moor Instruments, and HyperMed Imaging.PR NewswireWound-Healing Tech Innovator Nanomedic Technologies Appoints Prof. Jan Plock and Mark Darty to Advisory BoardNanomedic Technologies, an Israel-based medical therapeutics company specializing in Electrospun Healing Fiber (EHF™) technology for wound healing, has appointed Prof. Jan Plock and Mark Darty to its Advisory Board. Prof. Plock brings clinical expertise in microsurgery, burn reconstruction, and wound healing from his role as Chief of Plastic Surgery at Aarau Canton Hospital in Switzerland, while Mark Darty contributes experience in technology commercialization including his tenure as President and CEO of HyperMed Imaging. The appointments support the company's expansion of its Spincare System—a CE-cleared portable electrospinning wound treatment device—across Europe and preparations to enter the U.S. market.GlobeNewswireSANUWAVE Announces DFU Joint Investigational Partnership with HyperMedSANUWAVE Health announced a partnership with HyperMed to sponsor a clinical investigation on diabetic foot ulcers, expected to begin in August 2018. The trial will use HyperMed's Hyperview device to measure oxygenation and perfusion changes after dermaPACE treatment. The case series aims to quantify the system's mechanism of action.PR NewsChannelKênh Xem Trực Tiếp Bóng Đá XoilacTV HDXoilac TV is a Vietnamese online football streaming platform offering live matches, schedules, scores, and highlights. It covers major leagues like Premier League, La Liga, Serie A, Bundesliga, and Champions League, plus Vietnamese and international tournaments. The site provides device-friendly access and tools like live scores and highlights.